Use of an alkanoyl L-carnitine for the treatment of the erectile dysfunction

Abstract

Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin E1, pentolamine and papaverine.

1 - 12 . (canceled)  
     
     
         13 . A method of treating erectile dysfunction which comprises administering to a patient in need thereof a combination composition comprising as active ingredients propionyl L-carnitine or a pharmaceutically acceptable salt thereof and a drug useful for the treatment of erectile dysfunction selected from the group consisting of sildenafil, apomorphine prostaglandin E1, pentolamine and papaverine.  
     
     
         14 . The method of  claim 13 , wherein the pharmaceutically acceptable salt of propionyl L-carnitine is selected from the group consisting of chloride, bromide, orotate, acid aspartate, acid citrate, magnesium citrate, acid phosphate, fumarate, acid fumarate, magnesium fumarate, lactate, maleate, acid maleate, mucate, acid oxalate, pamoate, acid pamoate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino ethansulphonate, magnesium 2-amino etansulphonate, choline tartrate and trichloroacetate.  
     
     
         15 . The method of  claim 13  or  14 , in which the erectile dysfunction patient is affected by diabetes mellitus.  
     
     
         16 . The method of claims  13  or  14  in which the erectile dysfunction patient does not respond to treatment with drugs useful for the treatment of erectile dysfunction.  
     
     
         17 . The method of  claim 16 , in which the drug useful for the treatment of erectile dysfunction is selected from the group consisting of sildenafil, apomorphine prostaglandin E1, pentolamine and papaverine.  
     
     
         18 . A pharmaceutical composition comprising, as active ingredients, propionyl L-carnitine or a pharmaceutically acceptable salt thereof and a drug selected from the group consisting of sildenafil, apomorphine prostaglandin, pentolamine and papaverine and at least one excipient and/or pharmaceutically acceptable diluent.